These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23457670)

  • 1. Role of monoclonal antibodies in the treatment of asthma.
    O'Byrne PM
    Can Respir J; 2013; 20(1):23-5. PubMed ID: 23457670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma.
    Mitchell PD; El-Gammal AI; O'Byrne PM
    Clin Pharmacol Ther; 2016 Jan; 99(1):38-48. PubMed ID: 26502193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe asthma: future treatments.
    O'Byrne PM; Naji N; Gauvreau GM
    Clin Exp Allergy; 2012 May; 42(5):706-11. PubMed ID: 22515391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies for the treatment of refractory asthma.
    Hambly N; Nair P
    Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reassessing the Th2 cytokine basis of asthma.
    O'Byrne PM; Inman MD; Adelroth E
    Trends Pharmacol Sci; 2004 May; 25(5):244-8. PubMed ID: 15120489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
    D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial.
    De Boever EH; Ashman C; Cahn AP; Locantore NW; Overend P; Pouliquen IJ; Serone AP; Wright TJ; Jenkins MM; Panesar IS; Thiagarajah SS; Wenzel SE
    J Allergy Clin Immunol; 2014 Apr; 133(4):989-96. PubMed ID: 24582316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of omalizumab on markers of inflammation in patients with allergic asthma.
    Holgate S; Smith N; Massanari M; Jimenez P
    Allergy; 2009 Dec; 64(12):1728-36. PubMed ID: 19839977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal Antibodies for the Management of Severe Asthma.
    Rubinsztajn R; Chazan R
    Adv Exp Med Biol; 2016; 935():35-42. PubMed ID: 27334730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
    Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
    Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Omralizumab (Xolair) in severe persistent allergic asthma].
    Schleich F; Manise M; Louis R
    Rev Med Liege; 2009; 64(5-6):313-7. PubMed ID: 19642466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-IgE monoclonal antibody for the treatment of the asthma and other manifestations related to allergic diseases.
    Sarinho E; Cruz AA
    J Pediatr (Rio J); 2006 Nov; 82(5 Suppl):S127-32. PubMed ID: 17136288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
    Bousquet J; Cabrera P; Berkman N; Buhl R; Holgate S; Wenzel S; Fox H; Hedgecock S; Blogg M; Cioppa GD
    Allergy; 2005 Mar; 60(3):302-8. PubMed ID: 15679714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is new in antiimmunoglobulin E asthma therapy.
    Berger WE
    Allergy Asthma Proc; 2005; 26(6):428-34. PubMed ID: 16541964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.
    Dewilde S; Turk F; Tambour M; Sandström T
    Curr Med Res Opin; 2006 Sep; 22(9):1765-76. PubMed ID: 16968580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies.
    Katial RK; Bensch GW; Busse WW; Chipps BE; Denson JL; Gerber AN; Jacobs JS; Kraft M; Martin RJ; Nair P; Wechsler ME
    J Allergy Clin Immunol Pract; 2017; 5(2S):S1-S14. PubMed ID: 28143691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-IgE antibodies for the treatment of asthma.
    Buhl R
    Curr Opin Pulm Med; 2005 Jan; 11(1):27-34. PubMed ID: 15591885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma.
    Trivedi A; Pavord ID; Castro M
    Lancet Respir Med; 2016 Jul; 4(7):585-592. PubMed ID: 27230825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel monoclonal treatments in severe asthma.
    Meteran H; Meteran H; Porsbjerg C; Backer V
    J Asthma; 2017 Dec; 54(10):991-1011. PubMed ID: 28287273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.